Sermorelin Blood Work: Labs to Check Before & After

A 2023 cohort study published in the Journal of Clinical Endocrinology & Metabolism found that 34% of adults initiating growth hormone secretagogue therapy had undiagnosed glucose dysregulation that would have contraindicated treatment. All detectable through pre-therapy blood work. Sermorelin, a growth hormone-releasing hormone (GHRH) analog, doesn't just 'boost energy'. It directly stimulates the anterior pituitary to increase endogenous growth hormone (GH) secretion, which cascades into metabolic changes affecting glucose homeostasis, lipid metabolism, and protein synthesis. That mechanism is powerful enough to require medical oversight, and blood work is the foundation of that oversight.

Our team has guided hundreds of research subjects through peptide protocols. The gap between doing this right and doing it wrong comes down to three things most guides never mention: timing of blood draws relative to dosing, understanding what 'normal' IGF-1 ranges actually mean for your age, and knowing which secondary markers. Thyroid function, fasting glucose, lipid panels. Matter more than most prescribers admit upfront.

What blood work is required before starting sermorelin therapy?

Baseline sermorelin blood work labs check before after therapy typically include IGF-1 (insulin-like growth factor 1), fasting glucose, HbA1c, TSH (thyroid-stimulating hormone), and a comprehensive metabolic panel. IGF-1 is the primary efficacy marker. It reflects your body's GH output and serves as the benchmark for measuring sermorelin's effect. The glucose markers screen for diabetes or pre-diabetes, both of which are relative contraindications. TSH ensures thyroid function won't interfere with GH response, since hypothyroidism blunts pituitary GH secretion even when GHRH stimulation is adequate.

The standard definition of 'pre-treatment blood work' misses one critical detail: timing. IGF-1 has diurnal variation. It peaks in the morning and declines throughout the day. A blood draw at 8 AM vs 4 PM can show a 15–20% difference in the same person on the same day. That's why baseline labs should be drawn fasting, in the morning, before 10 AM whenever possible. This isn't about convenience. It's about establishing a reproducible reference point for all follow-up testing.

This article covers the specific labs required before and after sermorelin therapy, what each marker tells your prescriber about your candidacy and response, the timing protocols that most telemedicine providers don't explain, and the follow-up testing schedule that distinguishes medically supervised peptide therapy from unmonitored self-experimentation.

Why IGF-1 Is the Core Biomarker for Sermorelin Therapy

IGF-1 (insulin-like growth factor 1) is synthesised primarily in the liver in response to growth hormone. It's the downstream effector of GH's anabolic effects on muscle, bone, and connective tissue. When sermorelin stimulates your pituitary to release more GH, that GH circulates to the liver and triggers IGF-1 production. Measuring IGF-1 is more practical than measuring GH directly because GH is secreted in pulses. It spikes during sleep and in response to exercise, fasting, and stress, then drops back to near-undetectable levels within hours. A single GH blood test tells you almost nothing. IGF-1, by contrast, has a half-life of 12–15 hours and remains relatively stable throughout the day, making it a reliable marker of your overall GH status.

Baseline IGF-1 establishes where you're starting. Age-adjusted reference ranges are critical here. A 25-year-old with an IGF-1 of 180 ng/mL is at the low end of normal, but a 55-year-old with the same level is solidly mid-range. The goal of sermorelin isn't to push IGF-1 into supraphysiological territory (that's what exogenous GH does). It's to restore age-appropriate levels in people whose endogenous production has declined. Most prescribers target the upper half of the age-adjusted normal range, which for a 50-year-old typically means 150–250 ng/mL depending on the lab's specific reference intervals.

Follow-up IGF-1 testing happens at 8–12 weeks after starting therapy, then every 3–6 months during maintenance. If your IGF-1 rises from 140 ng/mL to 220 ng/mL at 12 weeks, that's a meaningful response. Sermorelin is working as intended. If it stays flat or rises minimally, that signals either inadequate dosing, poor pituitary reserve, or interference from another factor (hypothyroidism, chronic sleep deprivation, nutritional deficiency). Our experience working with peptide researchers shows that IGF-1 non-responders almost always have one of three issues: undertreated hypothyroidism, chronically elevated cortisol from stress or poor sleep, or dosing schedules that don't align with the body's natural GH pulse timing.

Glucose and Metabolic Markers: Screening for Contraindications

Growth hormone and IGF-1 both affect glucose metabolism. GH has an anti-insulin effect in the short term, meaning it can raise fasting blood sugar and reduce insulin sensitivity. That's not inherently dangerous in healthy individuals, but in someone with undiagnosed pre-diabetes or poorly controlled type 2 diabetes, sermorelin therapy can push glucose levels into the diabetic range or worsen existing glycemic control. That's why fasting glucose and HbA1c are non-negotiable components of sermorelin blood work labs check before after therapy.

Fasting glucose above 126 mg/dL on two separate tests, or HbA1c above 6.5%, meets the diagnostic criteria for diabetes and is a relative contraindication to sermorelin until glucose control is optimised. Pre-diabetes (fasting glucose 100–125 mg/dL or HbA1c 5.7–6.4%) isn't an absolute contraindication, but it requires closer monitoring. Follow-up glucose testing at 6–8 weeks is standard, and some prescribers will request a fasting insulin level or HOMA-IR score to assess insulin resistance more directly.

The comprehensive metabolic panel (CMP) screens for kidney and liver function. Both organs are involved in peptide clearance and metabolite processing. Elevated creatinine or reduced estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m² signals chronic kidney disease, which affects how peptides are cleared and can necessitate dose adjustments. Liver enzymes (ALT, AST) above twice the upper limit of normal are a red flag for hepatic impairment, which could interfere with IGF-1 synthesis since the liver is the primary production site.

Our team has reviewed this across hundreds of clients in this space. The pattern is consistent every time: prescribers who skip metabolic screening upfront end up managing preventable complications six months into therapy. Real Peptides prioritises quality and purity in every research-grade peptide we supply. That same precision applies to the clinical protocols surrounding their use.

Thyroid Function: The Overlooked Variable in GH Response

Thyroid-stimulating hormone (TSH) and, ideally, free T4 and free T3 are part of comprehensive sermorelin blood work labs check before after protocols for a reason most patients don't realise: hypothyroidism blunts the pituitary's response to GHRH stimulation. Even subclinical hypothyroidism. TSH above 4.5 mIU/L with normal free T4. Can reduce GH secretion by 20–30%, which means sermorelin's effectiveness is compromised before you've even started dosing.

The mechanism is bidirectional. Thyroid hormones regulate GH gene expression in the pituitary. Low thyroid function downregulates GH synthesis, so even when sermorelin binds to GHRH receptors and signals the pituitary to release GH, there's less GH available to release. Conversely, GH and IGF-1 affect thyroid hormone conversion in peripheral tissues, so changes in GH status can shift your thyroid function panel over time. That's why thyroid markers are rechecked at follow-up intervals alongside IGF-1.

If baseline TSH is elevated (above 4.5–5.0 mIU/L depending on lab reference ranges), most endocrinologists will recommend addressing thyroid function before initiating sermorelin. Thyroid replacement with levothyroxine or liothyronine takes 6–8 weeks to reach steady-state levels, and retesting TSH after that window confirms whether thyroid optimisation has occurred. Only then does sermorelin therapy proceed. Because treating one hormone deficiency while ignoring another is a setup for suboptimal results.

Additionally, free T3 levels matter more than many standard panels acknowledge. T3 is the active thyroid hormone, and some patients convert T4 to T3 poorly due to genetic polymorphisms in deiodinase enzymes. A patient with normal TSH and free T4 but low-normal free T3 may still have functional hypothyroidism that limits their GH response. Advanced prescribers will assess all three markers. TSH, free T4, and free T3. Before clearing someone for peptide therapy.

Sermorelin Blood Work Labs: Before vs After Comparison

Key Takeaways

• IGF-1 is the primary biomarker for sermorelin efficacy. Baseline establishes your starting point, and follow-up at 8–12 weeks confirms whether therapy is producing a measurable response.
• Fasting glucose and HbA1c screen for diabetes and pre-diabetes, both of which require optimisation before starting sermorelin due to GH's anti-insulin effects.
• Thyroid function (TSH, free T4, free T3) must be within optimal ranges. Hypothyroidism blunts pituitary GH response and will limit sermorelin's effectiveness.
• Timing of blood draws matters. IGF-1 should be measured fasting in the morning to ensure reproducibility across baseline and follow-up tests.
• Follow-up testing at 8–12 weeks and every 3–6 months thereafter is standard medical practice. Skipping it means you have no objective measure of whether the therapy is working.
• Comprehensive metabolic panels screen for kidney and liver function, both of which affect peptide clearance and IGF-1 synthesis capacity.

What If: Sermorelin Blood Work Scenarios

What If My Baseline IGF-1 Is Already in the Upper Half of the Normal Range?

Sermorelin may still be prescribed if you have symptoms of GH deficiency (fatigue, reduced muscle mass, poor recovery, cognitive fog) despite a mid-range IGF-1 level. Symptom burden often matters more than a single biomarker. Some prescribers interpret 'optimal' as the upper quartile of the age-adjusted range rather than just 'within normal limits,' especially for patients over 40. However, if your IGF-1 is already at 250 ng/mL and you're 50 years old, further increases offer minimal benefit and raise the risk of side effects like joint pain, fluid retention, or glucose dysregulation. In that case, addressing other factors. Sleep quality, cortisol management, thyroid optimisation. May yield better results than adding a GH secretagogue.

What If My Fasting Glucose Rises During Sermorelin Therapy?

A modest increase (5–10 mg/dL) is common and usually not clinically significant if you start with normal glucose metabolism. But if fasting glucose rises from 95 mg/dL to 110 mg/dL, or if HbA1c increases by 0.3% or more, that's a signal to recheck your diet, exercise, and sleep. GH's anti-insulin effect is being unmasked by poor metabolic health. Some prescribers will reduce the sermorelin dose or add metformin to improve insulin sensitivity. If glucose continues climbing despite interventions, discontinuing therapy is the medically appropriate response. The risks outweigh the benefits at that point.

What If My Follow-Up IGF-1 Doesn't Increase?

Non-response happens in 15–20% of patients and usually reflects one of four issues: inadequate dosing, poor pituitary reserve, untreated hypothyroidism, or interference from chronic stress and elevated cortisol. The first step is rechecking thyroid function (TSH, free T4, free T3) and reviewing sleep quality. GH is secreted primarily during deep sleep, and chronic sleep deprivation suppresses pituitary function regardless of GHRH stimulation. If thyroid and sleep are optimised, the prescriber may increase the dose or switch to a different secretagogue like CJC1295 Ipamorelin, which has a longer half-life and different receptor binding kinetics.

The Unflinching Truth About Sermorelin Blood Work

Here's the honest answer: most telemedicine peptide providers are cutting corners on lab work. The difference between a legitimate medical protocol and an unmonitored sales funnel is whether baseline and follow-up blood testing is actually required. Not suggested, not optional, but required before prescribing and at defined intervals during therapy. If a provider prescribes sermorelin based on a questionnaire alone, that's not medicine. It's a transaction.

Sermorelin isn't dangerous in the way anabolic steroids are, but it's also not risk-free. Growth hormone affects glucose metabolism, thyroid function, and fluid balance. In someone with undiagnosed diabetes, it can worsen glycemic control. In someone with subclinical hypothyroidism, it won't work as intended. In someone with normal IGF-1 who doesn't actually have GH deficiency, it's an expensive placebo with the potential for side effects like joint stiffness and carpal tunnel syndrome.

The prescribers who take this seriously. The ones who require fasting blood draws, interpret results in the context of age-adjusted reference ranges, and schedule follow-up testing at 8–12 weeks. Are the ones whose patients see consistent, measurable results without preventable complications. The rest are hoping you'll reorder monthly without asking questions. Blood work is the difference.

If the peptide protocols you're exploring don't involve lab oversight, you're not engaging in research-grade experimentation. You're self-experimenting without the data layer that makes it reproducible, safe, or scientifically valid. Our commitment to precision doesn't stop at peptide synthesis. You can explore the full range of high-purity research compounds we supply, including growth hormone modulators like MK 677 and metabolic peptides like Mazdutide, all manufactured with the same small-batch, exact-sequencing standards that define Real Peptides.

Sermorelin blood work labs check before after therapy isn't bureaucracy. It's the foundation of a medically sound protocol. Skip it, and you're operating on hope instead of data. The blood draw takes ten minutes. The insight it provides lasts the entire course of treatment.